Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic Administration for Adolescent Depression
NCT06898788Phase 1Recruiting
- Sponsor
- University of California, San Francisco
- Start
- May 2025
- Primary completion
- Aug 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Visbiome in major depressive disorder (MDD) (2 arms), sponsored by University of California, San Francisco. Primary endpoints: Left hippocampus-precuneus resting state functional connectivity at 8 weeks, Gut microbiome beta diversity at 8 weeks and 1 more. Started May 2025; status: recruiting.
02
Drugs
Visbiome
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06898788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898788.